XML 30 R6.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash Flows from Operating Activities    
Net Loss $ (16,892,385) $ (16,311,854)
Non-Cash Adjustments    
Depreciation and Amortization 1,795,782 946,335
Amortization of Software Development Costs in Cost of Sales - Products 75,000 75,000
Stock-Based Compensation 1,201,867 1,740,127
Loss on Disposal of Fixed Assets 0 56,836
Loss on Derivative Valuation 0 13,873
Impairment of Software Development Cost 0 196,223
Gain on Inventory Revaluation and Product Discontinuance 0 (211,416)
(Increase) Decrease in Operating Assets    
Accounts Receivable (193,053) (73,487)
Accrued Project Revenue (145,882) 497,784
Inventories (1,526,936) (2,950,276)
Vendor Prepayments (744,523) (358,997)
Prepaid Expenses and Other Assets 323,340 159,351
Increase (Decrease) in Operating Liabilities    
Accounts Payable (1,815,968) (1,718,578)
Accrued Expenses 14,212 (66,371)
Customer Deposits (152,362) 242,998
Unearned Revenue (29,144) 88,945
Income and Other Taxes Payable 38,557 26,779
Accrued Compensation 0 (327,469)
Accrued Interest 0 39,687
Net Cash Flows Used in Operating Activities (18,051,495) (17,934,510)
Cash Flows from Investing Activities    
Purchase of Fixed Assets (1,436,242) (886,713)
Investments in Patents and Trademarks (183,228) (323,347)
Investments in Licenses and Other Intangible Assets (807,079) (250,000)
Investments in Software Development 0 (87,500)
Net Cash Used in Investing Activities (2,426,549) (1,547,560)
Cash Flows from Financing Activities    
Proceeds from Exercise of Warrants 0 39,375
Proceeds from Common Stock Offerings 20,000,007 30,000,000
Issuance Costs on Common Stock Offerings (1,145,000) (1,975,000)
Net Cash Flows from Financing Activities 18,855,007 28,064,375
Net Increase (Decrease) in Cash and Cash Equivalents (1,623,037) 8,582,305
Cash and Cash Equivalents - Beginning of Period 17,263,643 14,889,636
Cash and Cash Equivalents - End of Period 15,640,606 23,471,941
Supplemental Disclosures    
Amortized Common Stock Expense in Accrued Expenses 28,577 0
Cumulative Revenue Adjustment - ASC 606 Adoption $ 0 $ 81,724